Cardiac angiosarcoma: A case report and review of current treatment

Primary cardiac angiosarcoma is a rare malignant cardiac neoplasm with early metastasis and poor prognosis. As there are currently no guidelines or effective therapeutic strategies, management of this condition depends on previous experiences of the clinician treating and the consideration of report...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2019-12, Vol.98 (49), p.e18193-e18193
Main Authors: Linfeng, Qian, Xingjie, Xu, Henry, Davies, Zhedong, Wan, Hongfei, Xu, Haige, Zhao
Format: Article
Language:English
Subjects:
Aged
Clinical Case Report
Echocardiography
Heart Atria - diagnostic imaging
Heart Atria - pathology
Heart Neoplasms - diagnostic imaging
Heart Neoplasms - pathology
Heart Neoplasms - surgery
Hemangiosarcoma - diagnostic imaging
Hemangiosarcoma - pathology
Hemangiosarcoma - surgery
Humans
Male
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary cardiac angiosarcoma is a rare malignant cardiac neoplasm with early metastasis and poor prognosis. As there are currently no guidelines or effective therapeutic strategies, management of this condition depends on previous experiences of the clinician treating and the consideration of reported cases. A 65-year-old male presented to our department with a 4-day history of chest tightness, dyspnea, lower extremity weakness and occasional dizziness, and a transthoracic echo (TTE) revealed a right atrium occupying mass. TTE showed right atrium occupation, and the post-operative histopathology showed the tumor to be a primary cardiac angiosarcoma. Right atrium tumor resection and right atrium reconstruction with a bovine pericardium were performed. The patient recovered from surgery and discharged but died 10 months after surgery because of complete resection was impossible and adjuvant therapy was not performed. Resection of primary cardiac angiosarcomas should be integrated with a combination of chemotherapy, radiotherapy, and targeted therapy based on tumor cell gene mutation and altered expression.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000018193